PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE • Drugs under development PART 08: MARKET SEGMENTATION BY PRODUCT • Segmentation by product • Comparison by product • Prescription – Market size and forecast 2017-2022 • OTC – Market size and forecast 2017-2022 • Market opportunity by product PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Customer preference for topical delivery • Use of different bases in topical drug delivery • Development of silicones for topical and transdermal drug delivery PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • GlaxoSmithKline • LEO Pharma • Merck Sharp & Dohme • Novartis • Pfizer PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global topical drugs market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global topical corticosteroids market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global topical corticosteroids market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Topical corticosteroids pipeline landscape Exhibit 19: Molecules in the pipeline Exhibit 20: Global topical corticosteroids market by product– Market share 2017-2022 (%) Exhibit 21: Comparison by product Exhibit 22: Prescription – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Prescription – Year-over-year growth 2018-2022 (%) Exhibit 24: OTC – Market size and forecast 2017-2022 ($ mn) Exhibit 25: OTC – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Global topical corticosteroids market by geography – Market share 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 31: Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 37: APAC – Year-over-year growth 2018-2022 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Market opportunity Exhibit 40: Population index 2000-2017 Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: GlaxoSmithKline: Overview Exhibit 47: GlaxoSmithKline – Business segments Exhibit 48: GlaxoSmithKline – Organizational development Exhibit 49: GlaxoSmithKline – Geographic focus Exhibit 50: GlaxoSmithKline – Segment focus Exhibit 51: GlaxoSmithKline – Key offerings Exhibit 52: LEO Pharma: Overview Exhibit 53: LEO Pharma – Business segments Exhibit 54: LEO Pharma – Organizational developments Exhibit 55: LEO Pharma – Geographic focus Exhibit 56: LEO Pharma – Segment focus Exhibit 57: LEO Pharma – Key offerings Exhibit 58: LEO Pharma – Key customers Exhibit 59: Merck Sharp & Dohme: Overview Exhibit 60: Merck Sharp & Dohme – Business segments Exhibit 61: Merck Sharp & Dohme – Organizational developments Exhibit 62: Merck Sharp & Dohme – Geographic focus Exhibit 63: Merck Sharp & Dohme – Segment focus Exhibit 64: Merck Sharp & Dohme – Key offerings Exhibit 65: Merck Sharp & Dohme – Key customers Exhibit 66: Novartis: Overview Exhibit 67: Novartis – Business segments Exhibit 68: Novartis – Organizational developments Exhibit 69: Novartis – Geographic focus Exhibit 70: Novartis – Segment focus Exhibit 71: Novartis – Key offerings Exhibit 72: Novartis – Key customers Exhibit 73: Pfizer: Overview Exhibit 74: Pfizer – Business segments Exhibit 75: Pfizer – Organizational developments Exhibit 76: Pfizer – Geographic focus Exhibit 77: Pfizer – Segment focus Exhibit 78: Pfizer – Key offerings Exhibit 79: Pfizer – Key customers

GlaxoSmithKline LEO Pharma Merck Sharp & Dohme Novartis Pfizer